1033718-91-0Relevant articles and documents
Asymmetric Synthesis of cis -(S, R)-3-Amino-4-fluoro-1-methylpyrrolidine
Bian, Jianwei,Cheung, Chiming,Fei, Zhongbo,Gao, Hongjun,Liu, Weipeng,Shen, Qirong,Xiong, Xin,Zhang, Jinzhu
supporting information, p. 1228 - 1230 (2019/06/08)
The development of the stereoselective synthesis of cis -(S, R)-3-amino-4-fluoro-1-methylpyrrolidine is described starting from chiral, non-racemic 1-[(3 S,4 S)-3-azido-4-hydroxypyrrolidin-1-yl]-2,2,2-trifluoroethan-1-one. Two sets of deoxyfluorination co
Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants
Planken, Simon,Behenna, Douglas C.,Nair, Sajiv K.,Johnson, Theodore O.,Nagata, Asako,Almaden, Chau,Bailey, Simon,Ballard, T. Eric,Bernier, Louise,Cheng, Hengmiao,Cho-Schultz, Sujin,Dalvie, Deepak,Deal, Judith G.,Dinh, Dac M.,Edwards, Martin P.,Ferre, Rose Ann,Gajiwala, Ketan S.,Hemkens, Michelle,Kania, Robert S.,Kath, John C.,Matthews, Jean,Murray, Brion W.,Niessen, Sherry,Orr, Suvi T. M.,Pairish, Mason,Sach, Neal W.,Shen, Hong,Shi, Manli,Solowiej, James,Tran, Khanh,Tseng, Elaine,Vicini, Paolo,Wang, Yuli,Weinrich, Scott L.,Zhou, Ru,Zientek, Michael,Liu, Longqing,Luo, Yiqin,Xin, Shuibo,Zhang, Chengyi,Lafontaine, Jennifer
, p. 3002 - 3019 (2017/04/24)
Mutant epidermal growth factor receptor (EGFR) is a major driver of non-small-cell lung cancer (NSCLC). Marketed first generation inhibitors, such as erlotinib, effect a transient beneficial response in EGFR mutant NSCLC patients before resistance mechani
PURINE DERIVATIVES
-
Paragraph 0695; 0706; 0707, (2015/05/26)
The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Q, G, ring A, ring B, R1, R2, R3, R4, R5, R5a, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, and m are defined herein. The novel purine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.
Synthesis and structure-activity relationships of 2-pyridones: II. 8- (fluoro-substituted pyrrolidinyl)-2-pyridones as antibacterial agents
Li, Qun,Wang, Weibo,Berst, Kristine B.,Claiborne, Akiyo,Hasvold, Lisa,Raye, Kathleen,Tufano, Michael,Nilius, Angela,Shen, Linus L.,Flamm, Robert,Alder, Jeff,Marsh, Kennan,Crowell, DeAnne,Chu, Daniel T.W.,Planner, Jacob J.
, p. 1953 - 1958 (2007/10/03)
The 8-position side chain of 2-pyridones is believed to be involved in the binding with bacterial DNA gyrase to form the ternary complex, making them very important for the activity of 2-pyridones. A series of 2-pyridones having fluoro-substituted amines at the 8-position has been synthesized and their antibacterial activities and parmacokinetic properties are reported.
Quinolizinone type compounds
-
, (2008/06/13)
Antibacterial compounds having the formula STR1 and the pharmaceutically acceptable salts, esters and amides thereof, preferred examples of which include those compounds wherein A is =CR6 --; R1 is cycloalkyl of from three to eight carbon atoms or substituted phenyl; R2 is selected from the group consisting of STR2 R3 is halogen; R4 is hydrogen, loweralkyl, a pharmaceutically acceptable cation, or a prodrug ester group; R5 is hydrogen, loweralkyl, halo(loweralkyl), or --NR13 R14 ; and R6 is halogen, loweralkyl, halo(loweralkyl), hydroxy-substituted loweralkyl, loweralkoxy(loweralkyl), loweralkoxy, or amino(loweralkyl), as well as pharmaceutical compositions containing such compounds and the use of the same in the treatment of bacterial infections.
